Harrow Inc Revenue Growth Rates (HROW), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Customers, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Harrow Inc   (NASDAQ: HROW)
 

HROW's Revenue Growth by Quarter and Year

Harrow Inc 's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

HROW Revenue (in millions $) FY 2026 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September -
2nd Quarter June 70.66
1st Quarter March 44.05
FY 114.71

HROWs Annual Revenue
Harrow Inc 's Revenue in the fiscal year 2025 $ 271.37 millions
Harrow Inc 's Revenue in the fiscal year 2024 $ 199.37 millions
Harrow Inc 's Revenue in the fiscal year 2023 $ 129.55 millions
Harrow Inc 's Revenue in the fiscal year 2022 $ 88.60 millions
Harrow Inc 's Revenue in the fiscal year 2021 $ 72.48 millions




HROW Revenue second quarter 2026 Y/Y Growth Comment
Harrow Inc reported Revenue increase of 11.26% year on year in the second quarter 2026, to $ 70.66 millions, this is lower than Harrow Inc 's recent average Revenue surge of 1402.39%.

Looking into second quarter 2026 results within Major Pharmaceutical Preparations industry 92 other companies have achieved higher Revenue growth. While Harrow Inc ' s Revenue growth of 11.26% ranks overall at the positon no. 1708 in the second quarter 2026.


HROW Revenue ( Y/Y Growth %) 2026
 2025 2024 2023
4th Quarter December - 33.31 % 83.8 % 78.85 %
3rd Quarter September - 44.05 % 43.98 % 49.87 %
2nd Quarter June 11.26 % 31.22 % 44.61 % 43.52 %
1st Quarter March -6.89 % 39.02 % 30.38 % 17.99 %
FY   - 36.44 % 52.54 % -

Financial Statements
Harrow Inc 's second quarter 2026 Revenue $ 70.66 millions HROW's Income Statement
Harrow Inc 's second quarter 2025 Revenue $ 63.51 millions Quarterly HROW's Income Statement


HROW Revenue (Quarter on Quarter Growth %)

 2026
 2025 2024 2023
4th Quarter December - 25.6 % 35.72 % 6.32 %
3rd Quarter September - 11.68 % 1.74 % 2.18 %
2nd Quarter June 60.41 % 34.24 % 42.23 % 28.24 %
1st Quarter March -50.56 % -29.21 % -6.41 % 28.38 %
FY (Year on Year)   - 36.44 % 52.54 % -


Back to HROW Growth rate Comparisons >> Back to HROW Growth rate Comparisons >>


Revenue second quarter 2026 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #93
Healthcare Sector #270
Overall #1708

Revenue Y/Y Growth Statistics
High Average Low
36059.78 % 1402.39 % -4.48 %
(Mar 31 2015)   (Dec 31 2020)
Revenue second quarter 2026 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #93
Healthcare Sector #270
Overall #1708
Revenue Y/Y Growth Statistics
High Average Low
36059.78 % 1402.39 % -4.48 %
(Mar 31 2015)   (Dec 31 2020)

Revenue by Quarter for the Fiscal Years 2023, 2024, 2025, 2026

Harrow Inc 's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
47254.68 % 884.94 % -100 %
(Jun 30 2014)  


HROW's II. Quarter Q/Q Revenue Comment
Harrow Inc achieved in the II. Quarter 2026 below company average Revenue jump of 60.41% quarter on quarter, to $ 70.66 millions.

Although the II. Quarter 2026 Revenue Q/Q growth was lower than the regular , this has been yet encouraging story, as the II. Quarter surge, eclipses the 34.24% growth in the II. Quarter a year ago

Within Major Pharmaceutical Preparations industry 28 other companies have achieved higher Revenue quarter on quarter growth. While Harrow Inc 's Revenue growth quarter on quarter, overall rank is 220.


Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #29
Healthcare Sector #60
Overall #220
Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #29
Healthcare Sector #60
Overall #220
Revenue Q/Q Growth Statistics
High Average Low
47254.68 % 884.94 % -100 %
(Jun 30 2014)  


HROW's II. Quarter Q/Q Revenue Comment
Harrow Inc achieved in the II. Quarter 2026 below company average Revenue jump of 60.41% quarter on quarter, to $ 70.66 millions.

II. Quarter 2026 Revenue Q/Q growth were paradoxical, although lower than the regular, yet it demonstrates absolute recovery measured to the 34.24% in the II. Quarter a year ago.

Within Major Pharmaceutical Preparations industry 28 other companies have achieved higher Revenue quarter on quarter growth. While Harrow Inc 's Revenue growth quarter on quarter, overall rank is 220.


Harrow Inc 's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Jun 30 2026)		 12 Months Ending
(Mar 31 2026)		 12 Months Ending
(Dec 31 2025)		 12 Months Ending
(Sep 30 2025)		 12 Months Ending
(Jun 30 2025)
Cumulative Revenue 12 Months Ending $ 274.72 $ 267.58 $ 270.84 $ 248.58 $ 226.89
Y / Y Revenue Growth (TTM) 21.08 % 26.35 % 36.44 % 47.94 % 48.31 %
Year on Year Revenue Growth Overall Ranking # 317 # 275 # 129 # 246 # 144
Seqeuential Revenue Change (TTM) 2.67 % -1.2 % 8.96 % 9.56 % 7.14 %
Seq. Revenue Growth (TTM) Overall Ranking # 1710 # 1745 # 441 # 1152 # 774


Cumulative Revenue growth Comment
With the quarterly Revenue reported in the Jun 30 2026 period, Harrow Inc 's cumulative twelve months Revenue were $ 275 millions, company would post below average annual Revenue growth of 7.14% year on year, if the fiscal year would end at Jun 30 2026.
A slow-down in the Harrow Inc 's Revenue growth from the 44.05% growth in Mar 31 2026.

In the Healthcare sector 87 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 275 to 317.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 93
Healthcare Sector # 88
Overall # 317

Revenue TTM Y/Y Growth Statistics
High Average Low
36059.78 %
 1402.39 %
-4.48 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 93
Sector # 270
S&P 500 # 1710
Cumulative Revenue growth Comment
With the quarterly Revenue reported in the Jun 30 2026 period, Harrow Inc 's cumulative twelve months Revenue were $ 275 millions, company would post below average annual Revenue growth of -4.48% year on year, if the fiscal year would end at Jun 30 2026.
A slow-down in the Harrow Inc 's Revenue growth from the 44.05% growth in Mar 31 2026.

In the Healthcare sector 87 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 275 to 317.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 93
Healthcare Sector # 88
Overall # 317

Revenue TTM Y/Y Growth Statistics
High Average Low
36059.78 %
1402.39 %
-4.48 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 93
Sector # 270
S&P 500 # 1710




Other Revenue Growth
Major Pharmaceutical Preparations Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
HROW's Revenue Growth Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue jump for the quarter ending Jun 30 2026 within Healthcare SectorY/Y Change %Revenue for the quarter ending Jun 30 2026
Cannapharmarx Inc 19.26%$ 19.261 millions
Anika Therapeutics Inc 19.18%$ 19.176 millions
Bioaffinity Technologies Inc 18.99%$ 18.992 millions
Aurinia Pharmaceuticals Inc 18.87%$ 18.872 millions
Camp4 Therapeutics Corporation18.84%$ 18.838 millions
Lensar Inc 18.37%$ 18.371 millions
Immunocore Holdings Plc18.34%$ 18.336 millions
Innovage Holding Corp 18.31%$ 18.307 millions
Koru Medical Systems Inc 18.15%$ 18.153 millions
Clearpoint Neuro Inc 18.07%$ 18.068 millions
Avita Medical Inc 17.83%$ 17.830 millions
Xencor Inc17.46%$ 17.458 millions
Logicmark Inc17.39%$ 17.387 millions
Ensign Group Inc17.33%$ 17.325 millions
Medpace Holdings Inc 17.24%$ 17.242 millions
Geron Corporation17.22%$ 17.220 millions
Si bone inc 17.16%$ 17.159 millions
Cvrx inc 16.77%$ 16.766 millions
Regeneron Pharmaceuticals Inc 16.73%$ 16.735 millions
Invo Fertility Inc 16.73%$ 16.732 millions
Pro dex Inc 16.65%$ 16.646 millions
Royalty Pharma Plc16.50%$ 16.499 millions
Acadia Pharmaceuticals Inc 16.40%$ 16.402 millions
Harvard Bioscience Inc 16.35%$ 16.352 millions
Alpha Pro Tech Ltd 15.76%$ 15.765 millions
Armata Pharmaceuticals Inc 15.72%$ 15.722 millions
Lifeward ltd 15.71%$ 15.706 millions
Novocure Limited15.60%$ 15.603 millions
Ufp Technologies Inc 15.56%$ 15.558 millions
Orthopediatrics Corp15.55%$ 15.551 millions


About Harrow Inc Revenue Growth Rates (HROW), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

What’s included here

Company: Harrow Inc (CIK 1360214).

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Accession: 0001628280-26-055271
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: Harrow Inc’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.